Table 1. Participants characteristics.
| Study Participants | Biological Sex | Age (years) | HIV infection status | Time to ART initiation (months) | Duration of ART (years) | CD4 Count (/mm3 blood) | CD4 Nadir (/mm3 blood) | CD4/CD8 Ratio | HIV RNA (copies/mL) | Integrated HIV DNA (copies/million PBMC) |
|---|---|---|---|---|---|---|---|---|---|---|
| 3693 | Male | 46 | Positive | 0.9 | 1.2 | 841 | 468 | 0.94 | < 40 | 4 |
| 2641 | Male | 60 | Positive | 4.2 | 2.8 | 341 | 252 | 0.74 | < 40 | 53 |
| 2609 | Male | 33 | Positive | 1.7 | 1.5 | 899 | 518 | 1.51 | < 40 | 129 |
| 2647 | Male | 33 | Positive | 4.5 | 3.4 | 532 | 486 | 1.34 | < 40 | 294 |
| 2531 | Male | 51 | Positive | 1.9 | 3.4 | 1163 | 618 | 1.9 | < 40 | 48 |
| 2664 | Male | 46 | Positive | 4.1 | 2.7 | 637 | 509 | 0.96 | < 40 | <63 |
| 2606 | Male | 29 | Positive | 1.7 | 3.5 | 787 | 341 | 1.68 | < 40 | 563 |
| 2454 | Male | 35 | Positive | 0.7 | 7.1 | 513 | 352 | 1.31 | < 40 | 25 |
| 2661 | Male | 54 | Positive | 3.4 | 12.9 | 739 | 442 | 1.02 | < 40 | 463 |
| 2522 | Male | 42 | Positive | 4.4 | 6.4 | 341 | 203 | 0.81 | < 40 | 485 |
| 1473 | Male | 55 | Positive | 34.9 | 4.5 | 573 | 311 | 1.32 | < 40 | 1144 |
| 1408 | Male | 31 | Positive | 45.5 | 3.1 | 637 | 357 | 1.14 | < 40 | 292 |
| 1602 | Male | 38 | Positive | 24.4 | 3.5 | 626 | 480 | 2.3 | < 40 | 14 |
| 3632 | Male | 31 | Positive | 20.8 | 1.8 | 902 | 664 | 1.74 | < 40 | 100 |
| 1756 | Male | 29 | Positive | 6.8 | 4.1 | 582 | 229 | 0.97 | < 40 | <76 |
| 1597 | Male | 56 | Positive | 187.7 | 2.6 | 432 | 335 | 0.6 | < 40 | 247 |
| 2610 | Male | 53 | Positive | 34.8 | 2.6 | 468 | 393 | 1.07 | < 40 | 1887 |
| 2026 | Male | 61 | Positive | 85.5 | 16.7 | 383 | 132 | 0.67 | < 40 | 28 |
| 2168 | Male | 55 | Positive | 222 | 13.4 | 377 | 300 | 0.35 | < 40 | 151 |
| 2013 | Male | 67 | Positive | 122.5 | 18.8 | 687 | 13 | 1.35 | < 40 | 121 |
| 2185 | Male | 59 | Positive | 39.1 | 11.5 | 523 | 2 | 1.37 | < 40 | 69 |
| 2046 | Male | 51 | Positive | 69.4 | 17 | 747 | 10 | 0.76 | < 40 | 258 |
| 2274 | Male | 54 | Positive | 13.1 | 11.8 | 486 | 280 | 1.23 | < 40 | 152 |
| 2208 | Male | 64 | Positive | 114.5 | 7.1 | 437 | 54 | 0.98 | < 40 | 374 |
| Median | - | 51 | - | 20.8 | 4.1 | 573 | 335 | 1.14 | < 40 | 140 |
| [IQR] | [33-56] | [4.1-69.4] | [2.8-11.8] | [437-739] | [203-480] | [0.81-1.37] | [56-354] | |||
| 1806 | Male | 58 | Negative | NA | NA | 736 | NA | 3.05 | NA | NA |
| 1852 | Male | 39 | Negative | NA | NA | 1570 | NA | 1.65 | NA | NA |
| 1867 | Male | 63 | Negative | NA | NA | 584 | NA | 1.42 | NA | NA |
| 1943 | Male | 61 | Negative | NA | NA | 1677 | NA | 2.28 | NA | NA |
| 6532 | Male | 62 | Negative | NA | NA | 957 | NA | 2.29 | NA | NA |
| 6561 | Male | 53 | Negative | NA | NA | 573 | NA | 1.99 | NA | NA |
| Median | - | 59.5 | - | - | - | 847 | - | 2.1 | - | - |
| [IQR] | [50-62] | [581-1597] | [1.6-2.5] |
Abbreviations: ART, antiretroviral therapy; CD4, CD4+ T cell; CD8, CD8+ T cell; DNA, deoxyribonucleic acid; HIV, human immunodeficiency virus; IQR, 25–75% interquartile range; PBMC, peripheral blood mononuclear cells; RNA, ribonucleic acid.